Ongoing epidemiological studies


PREDIMAR is an intervention study on secondary prevention of atrial fibrillation. The aim is to reduce the percentage of relapses that occur after an ablation.

This study will include patients with paroxysmal atrial fibrillation (with at least one episode during the last year) or with persistent atrial fibrillation who are operated on with ablation.

The PREDIMAR project is an intervention study comparing two diet-based strategies. A dietitian with experience in this type of study will be responsible for carrying out these interventions. Patients will be randomly assigned to one of the two groups being compared in this study. The difference between the two groups is the level of intensity and frequency with which the dietitian will contact the patients. Both interventions will have a maximum duration of two years.


PREDIMED-PLUS is a randomized primary cardiovascular prevention trial testing the effect of an intensive lifestyle intervention with an energy-reduced Mediterranean diet, increased physical activity, and behavioural treatment with goals for weight loss versus a control group receiving a Mediterranean diet without energy reduction, any special intervention on physical activity and no goals for weight loss in 6874 Spanish men and women with metabolic syndrome. The end-point is a composite cardiovascular outcome including myocardial infarction, stroke or cardiovascular death. Randomization started in October 2013 and the completion date will be December 2022.


The LifeBreast trial is the first Spanish large-scale, multicenter randomized trial to test whether adopting a Mediterranean or a low-fat diet among women, who are diagnosed with early-stage breast cancer, reduces the risk for breast cancer recurrence. 

Eligible women are randomized to a Mediterranean diet or a low-fat dietary pattern intervention group for a maximum duration of two years.  A group of registered dietitians are involved in the trial. 

Changes in circulating tumor cells, inflammatory biomarkers, oxidative stress and quality of life will be evaluated after the intervention period, apart from other outcome measures. The utmost target of the LifeBreast trial is to impact women’s lives through groundbreaking research.